Chimeric Therapeutics (ASX:CHM) expands cancer trials
18 May 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on clinical trial progression, and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.